Injectable Hydrogel for Cu²⁺ Controlled Release and Potent Tumor Therapy.

Area of Science:

• Biomaterials Science
• Drug Delivery Systems
• Cancer Therapeutics

Background:

• Disulfiram (DSF) shows anti-tumor activity dependent on copper ions (Cu²⁺).
• Copper toxicity and unpredictable distribution limit in vivo efficacy of DSF.
• A controlled Cu²⁺ delivery system is needed to optimize DSF's anti-cancer mechanism.

Purpose of the Study:

• To design and evaluate an injectable hydrogel system for controlled Cu²⁺ release (CRC).
• To enhance the anti-tumor efficacy of disulfiram (DSF) through targeted copper delivery.
• To develop a novel therapeutic strategy for cancer treatment.

Main Methods:

• Fabrication of a CRC system using agarose hydrogels encapsulating CuCl₂ and hierarchical microparticles (HMP).
• Utilizing 808 nm laser irradiation to induce hydrogel hydrolysis and controlled Cu²⁺ release via photothermal effect.
• Investigating the synergistic effect of released Cu²⁺ and pre-injected DSF on tumor suppression.

Main Results:

• The CRC system successfully controlled Cu²⁺ release upon laser stimulation.
• The photothermal effect of the laser triggered hydrogel hydrolysis, enabling localized Cu²⁺ delivery.
• The combined approach demonstrated potential for suppressing tumor progression.

Conclusions:

• The developed CRC system offers an innovative approach for targeted Cu²⁺ delivery in cancer therapy.
• This hydrogel-based system provides a tunable platform for optimizing disulfiram's anti-tumor effects.
• The study highlights the potential of photothermally-responsive hydrogels in advanced drug delivery.